Literature DB >> 2674086

Impact of initial quality control review on study outcome in lung and head/neck cancer studies--review of the Radiation Therapy Oncology Group experience.

P E Wallner1, R A Lustig, T F Pajak, G Robinson, L W Davis, C A Perez, H G Seydel, V A Marcial, G E Laramore.   

Abstract

The Radiation Therapy Oncology Group (RTOG) initiated cooperative clinical trials in 1971. In 1978, RTOG developed a formalized program of Quality Control (QC) divided into initial and final phases. The initial review process consisted of two steps. The first phase of review is an evaluation performed by a radiation oncologist to verify treatment plan and field borders. The second portion of the initial review process originally consisted of dosimetry calculation verification based on machine data provided by the regional Radiological Physics Center and treatment planning data provided by the accessioning institution. Between 1978 and December 31, 1987, a total of 11,343 cases in 96 RTOG protocols, excluding particle studies, underwent initial review. Of this number, 2227 patients were entered in lung cancer studies and 1341 patients were entered in head/neck cancer studies. Initial review was carried out in 2089 (93.8%) of the lung cancer cases. Missing or delayed data accounted for 138 (6.2%) cases not reviewed initially. In head/neck cancer trials, 1251 (93.2%) received initial review and 90 (6.8%) did not. Our findings suggest that there are sharply defined but long lasting learning experiences involved in clinical trial participation. Consideration may be given to modifying the initial review process to use random sampling of cases accessioned by experienced investigators in ongoing clinical trials and to continuing the total case evaluation on all new studies and cases entered by inexperienced investigators or investigators/institutions with unsatisfactory performance. Recommendations regarding initial review of other sites will await evaluation of the impact of initial review on those sites.

Entities:  

Mesh:

Year:  1989        PMID: 2674086     DOI: 10.1016/0360-3016(89)90084-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303.

Authors:  Naoko Sanuki; Satoshi Ishikura; Masayuki Shinoda; Yoshinori Ito; Kazushige Hayakawa; Nobutoshi Ando
Journal:  Int J Clin Oncol       Date:  2011-06-14       Impact factor: 3.402

Review 2.  What we have learned: the impact of quality from a clinical trials perspective.

Authors:  Thomas J FitzGerald
Journal:  Semin Radiat Oncol       Date:  2012-01       Impact factor: 5.934

3.  Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202.

Authors:  Naoko Sanuki-Fujimoto; Satoshi Ishikura; Kazushige Hayakawa; Kaoru Kubota; Yutaka Nishiwaki; Tomohide Tamura
Journal:  Radiat Oncol       Date:  2009-06-02       Impact factor: 3.481

4.  Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study.

Authors:  Steffi U Pigorsch; Severin Kampfer; Markus Oechsner; Michael C Mayinger; Petra Mozes; Michal Devecka; Kerstin K Kessel; Stephanie E Combs; Jan J Wilkens
Journal:  Radiat Oncol       Date:  2020-11-02       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.